Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors

A compound of formula (I):

• or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
• Q is O or S;
• R1 is a 6-membered heteroaryl group containing at least two nitrogen atoms in the 6-membered ring structure, wherein the 6-membered heteroaryl group of R1 is substituted with at least one monovalent group X, wherein X is at each occurrence any group that can mesomerically donate a lone pair of electrons from a nitrogen, oxygen or sulphur atom onto at least one nitrogen atom in the 6-membered ring structure, and wherein the 6-membered heteroaryl group may optionally be further substituted;
• and
• R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted, provided that the substitutent at the a-position is not an optionally substituted monovalent heterocyclic group or an optionally substituted monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the α-ring atom of the cyclic group.